- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
High-flying Hologic splits stock
Bone densitometry firm Hologic of Waltham, MA, announced a two-for-onestock split effective March 25. Hologic's share price has risensteadily since last year, when Merck received marketing approvalfor its Fosamax osteoporosis drug, and the split will
Bone densitometry firm Hologic of Waltham, MA, announced a two-for-one
stock split effective March 25. Hologic's share price has risen
steadily since last year, when Merck received marketing approval
for its Fosamax osteoporosis drug, and the split will make the
company's stock more affordable. Hologic's stock was trading at
around $50 a share the week before the split. It had been trading
at around $14 a share last March (SCAN 12/27/95).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
